BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Breno Bittencourt de Brito, Filipe Antônio França da Silva, Aline Silva Soares, Vinícius Afonso Pereira, Maria Luísa Cordeiro Santos, Mariana Miranda Sampaio, Pedro Henrique Moreira Neves, Fabrício Freire de Melo. Pathogenesis and clinical management of <i>Helicobacter pylori</i> gastric infectionWorld Journal of Gastroenterology 2019; 25(37): 5578-5589 doi: 10.3748/wjg.v25.i37.5578
2
Ju Yup Lee, Kyung Sik Park. Optimal First-Line Treatment forHelicobacter pyloriInfection: Recent StrategiesGastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/9086581
3
Jing Su, Xiaoying Zhou, Han Chen, Bo Hao, Weifeng Zhang, Guoxin Zhang. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infectionMedicine 2017; 96(7): e5859 doi: 10.1097/MD.0000000000005859
4
Huseyin Alkim, Ali Riza Koksal, Salih Boga, Ilker Sen, Canan Alkim. Role of Bismuth in the Eradication of Helicobacter pyloriAmerican Journal of Therapeutics 2017; 24(6): e751 doi: 10.1097/MJT.0000000000000389
5
Thomas A. VanDruff. Management of Select ThrombocytopeniasAACN Advanced Critical Care 2019; 30(2): 165 doi: 10.4037/aacnacc2019186
6
Ryusuke Horie, Osamu Handa, Takashi Ando, Takuya Ose, Takaaki Murakami, Norihisa Suzuki, Rei Sendo, Eiko Imamoto, Yoshito Itoh. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan Helicobacter 2020; 25(4) doi: 10.1111/hel.12698
7
Pramodini B. Kale-Pradhan, Anela Mihaescu, Sheila M. Wilhelm. Fluoroquinolone Sequential Therapy forHelicobacter pylori: A Meta-analysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2015; 35(8): 719 doi: 10.1002/phar.1614
8
Antonio Cuadrado-Lavín, J. Ramón Salcines-Caviedes, Ainhoa Diaz-Perez, Miguel F. Carrascosa, María Ochagavía, José Luis Fernandez-Forcelledo, Marta Cobo, Pedro Fernández-Gil, Blanca Ayestarán, Blanca Sánchez, Cristina Campo, Javier Llorca, Silvia Lorenzo, Aitziber Illaro. First-line eradication rates comparing two shortened non-bismuth quadruple regimens againstHelicobacter pylori: an open-label, randomized, multicentre clinical trialJournal of Antimicrobial Chemotherapy 2015; 70(8): 2376 doi: 10.1093/jac/dkv089
9
Rocco Maurizio Zagari, Marco Romano, Veronica Ojetti, Reinhold Stockbrugger, Sergio Gullini, Bruno Annibale, Fabio Farinati, Enzo Ierardi, Giovanni Maconi, Massimo Rugge, Carlo Calabrese, Francesco Di Mario, Francesco Luzza, Stefano Pretolani, Antonella Savio, Giovanni Gasbarrini, Michele Caselli. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015Digestive and Liver Disease 2015; 47(11): 903 doi: 10.1016/j.dld.2015.06.010
10
Kokab Namkin, Mahmood Zardast, Fatemeh Basirinejad. Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From IranIranian Journal of Pediatrics 2016; 26(1) doi: 10.5812/ijp.3768
11
Phoebe Aitila, Michael Mutyaba, Simon Okeny, Maurice Ndawula Kasule, Rashid Kasule, Frank Ssedyabane, Benson Okongo, Richard Onyuthi Apecu, Enoch Muwanguzi, Caesar Oyet. Prevalence and Risk Factors ofHelicobacter pyloriInfection among Children Aged 1 to 15 Years at Holy Innocents Children’s Hospital, Mbarara, South Western UgandaJournal of Tropical Medicine 2019; 2019: 1 doi: 10.1155/2019/9303072
12
Frank J Senatore, Jonathan Wilmot, John W Birk. Helicobacter pyloritreatment: Still a work in progressPostgraduate Medicine 2016; 128(1): 152 doi: 10.1080/00325481.2016.1103194
13
Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Akira Nishimura, Koki Nakamura, Setsuo Hasegawa. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover StudyAdvances in Therapy 2016; 33(9): 1519 doi: 10.1007/s12325-016-0374-x
14
Ethel Zimberg  Chehter. Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?Gastroenterology & Hepatology: Open Access 2014; 1(2) doi: 10.15406/ghoa.2014.01.00011
15
Rosalie Allison, Donna M. Lecky, Megan Bull, Kim Turner, Gauri Godbole, Cliodna A. M. McNulty. Audit ofHelicobacter pyloriTesting in Microbiology Laboratories in England: To Inform Compliance with NICE Guidance and the Feasibility of Routine Antimicrobial Resistance SurveillanceInternational Journal of Microbiology 2016; 2016: 1 doi: 10.1155/2016/8540904